Pooled analysis of single-arm studies of Budesonide/Glycopyrronium/Formoterol (BGF) in routine care setting - CHOROS
Study identifier:D5980R00084
ClinicalTrials.gov identifier:NCT06712563
EudraCT identifier:N/A
CTIS identifier:N/A
Recruiting
Official Title
Pooled analysis of multi-country, open-label single-arm, non-interventional, multi-center, cohort studies of real-world outcomes in new users of Budesonide/Glycopyrronium/Formoterol (BGF) in routine care setting
Medical condition
Pulmonary Disease, Chronic Obstructive
Phase
N/A
Healthy volunteers
No
Study drug
Budesonide/glycopyrrolate/formoterol fumarate
Sex
All
Estimated Enrollment
2000
Study type
Observational
Age
18 Years - n/a
Date
Study Start Date: 17 Apr 2025
Estimated Primary Completion Date: 04 Sept 2026
Estimated Study Completion Date: 04 Sept 2026
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jul 2025 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
IQVIA
Inclusion and exclusion criteria
Loading...
Sort by status
- All Statuses
- Recruiting
- Not yet recruiting
- Recruiting complete
- Completed
- Other
No locations available
| Arms | Assigned Interventions |
|---|---|
| BGF Initiators New initiators of BGF without prior BGF exposure | - |
Contacts
Investigators
Principal Investigator
Michael F Pollack
AstraZeneca
